Skip to content

Author

Xiaojun Yao

We have 4 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

AI virtual cells for drug discovery and pharmacology.

The resources and modeling advances supporting AI virtual cells' value for mechanism-of-action analysis, efficacy, safety, resistance, and combination studies are reviewed, and evidence requirements for pharmacological use are defined.

Shi-Hang Wang, Yang Zhang, Dong Wang et al. · 0 citations
Open access Jul 2026

Structure-Based Design of New Nonpeptidic Covalent Mpro Inhibitors against SARS-CoV-2 and Omicron Variants

The structure-based covalent modifications that generate new nonpeptidic covalent Mpro inhibitors are described that may support the deuterated compound as a new lead for developing anti-SARS-CoV-2 drugs and further reveal the feasibility of using chloroacetyl for structure-based covalent drug design.

Honglei Bao, Ling-Chen Sun, Shi-Lin Gong et al. · 0 citations
Jul 2026

TPS-Flow: Physics-Guided Flow-Based Generative Modeling of Protein Transition Paths.

TPS-Flow is presented, a physics-guided flow-based generative framework for end point-conditioned conformational path sampling between predefined protein states (not equilibrium ensembles), thereby bridging atomistic simulation and deep generative modeling of protein transition paths.

Kai Xu, Likun Zhao, Yanan Tian et al. · 0 citations
Aug 2026

Discovery of novel RIPK3 inhibitors by virtual screening and bioactivity evaluation.

An integrated virtual screening strategy based on molecular fingerprint similarity, pharmacophore models, molecular docking, and molecular dynamics simulation is proposed and three promising lead compounds targeting RIPK3 for AD treatment are offered.

Cheng-Gong Fu, Qin Li, Yu-Wei Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.